Spiriva (tiotropium bromide) is a long-acting muscarinic antagonist (LAMA) that is the cornerstone maintenance therapy for COPD. It is one of the most widely prescribed respiratory medications globally, providing 24-hour bronchodilation.
Spiriva blocks M3 muscarinic receptors in airway smooth muscle, preventing acetylcholine-mediated bronchoconstriction. Provides sustained 24-hour bronchodilation with once-daily dosing.
Annual revenue trajectory
Revenue of competing drugs in the same class
2 indications
All approved therapeutic uses
Spiriva is the most prescribed LAMA globally for COPD maintenance. Facing competition from triple combo inhalers (Trelegy) but retains strong volume position, especially in emerging markets.
Revenue stable at $9-10B. Generic competition in some markets but brand loyalty and device preference (HandiHaler/Respimat) sustain revenue. Boehringer developing new respiratory combinations.
| Drug | Company | Revenue |
|---|---|---|
| Anoro (umeclidinium/vilanterol) | GSK | $3.0B |
| Trelegy (fluticasone/umeclidinium/vilanterol) | GSK | $5.0B |
| Breo (fluticasone/vilanterol) | GSK | $1.5B |
| Duaklir (aclidinium/formoterol) | AstraZeneca | $0.3B |
Revenue figures from company annual reports (FY2023). Clinical trial data from ClinicalTrials.gov. Competitive intelligence from Evaluate Pharma World Preview 2024 and IQVIA MIDAS. Market analysis by Medifirm Intelledge Global.